Acceptance, availability, and feasibility of RTS, S/AS01 malaria vaccine: A review.
AS01
Plasmodium
RTS, S
malaria
vaccine
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
22
02
2023
received:
17
11
2022
accepted:
13
05
2023
medline:
30
6
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
In malaria-stricken regions, malaria continues to be one of the primary causes of mortality for children. The number of malaria-related fatalities has drastically decreased because of artemisinin-based pharmacological regimens. Two independent researchers did a comprehensive literature search using PubMed/MEDLINE and Google Scholar from its inception to September 2022. After evaluating RTS, S/AS01 for its safety, effectiveness, and feasibility, the European Medicines Agency (EMA) issued a favorable conclusion. It was suggested that the RTS, S malaria vaccine be used extensively by the World Health Organization on October 6, 2021. The successful pilot program testing the malaria vaccine in Ghana, Kenya, and Malawi served as the basis for this proposal. Several challenges need to be addressed to ensure the success of vaccination programs. From the acceptability perspective, issues such as inadequate community engagement, concerns about side effects, and issues with the delivery and quality of healthcare services can affect the acceptance of the vaccine. From the feasibility standpoint, factors such as lack of transportation or long distances to healthcare facilities and the perception of completion of the vaccination calendar can affect the feasibility of the vaccine. Lastly, the availability of the vaccine is also a major concern as it may not be readily available to meet the demands.
Identifiants
pubmed: 37382251
doi: 10.1002/iid3.899
pmc: PMC10266133
doi:
Substances chimiques
Malaria Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e899Informations de copyright
© 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Malar J. 2012 Nov 28;11:394
pubmed: 23186030
Vaccine. 2018 Jun 14;36(25):3576-3577
pubmed: 28385607
Malar J. 2020 Jun 24;19(1):226
pubmed: 32580719
PLoS One. 2014 Oct 15;9(10):e109707
pubmed: 25334094
Ther Adv Infect Dis. 2021 Nov 01;8:20499361211054923
pubmed: 34745608
Malar J. 2016 Apr 05;15:189
pubmed: 27048260
Malar J. 2021 Apr 13;20(1):183
pubmed: 33849572
Malar J. 2013 May 07;12:156
pubmed: 23651533
Hum Vaccin Immunother. 2019;15(10):2386-2398
pubmed: 31012786
Lancet. 2016 Apr 2;387(10026):1376
pubmed: 27115819
Trop Med Health. 2017 Jan 14;45:2
pubmed: 28104997
Vaccines (Basel). 2021 Aug 23;9(8):
pubmed: 34452061
Malar J. 2014 May 05;13:172
pubmed: 24886650
Malar J. 2011 May 30;10:147
pubmed: 21624117
Vaccine. 2020 Apr 16;38(18):3411-3421
pubmed: 32192811
PLoS One. 2018 Dec 31;13(12):e0209744
pubmed: 30596732
Malar J. 2022 May 12;21(1):146
pubmed: 35549710
Vaccine. 2017 Jul 13;35(32):3982-3987
pubmed: 28623028
Trials. 2014 Feb 25;15:65
pubmed: 24565019
PLoS Med. 2016 Apr 12;13(4):e1001994
pubmed: 27070151
Hum Vaccin Immunother. 2020 Mar 3;16(3):480-489
pubmed: 31545128
Am J Public Health. 2005 Jul;95(7):1123-7
pubmed: 15983268
Vaccine. 2022 Jan 24;40(3):397-402
pubmed: 34955324
Drugs Ther Perspect. 2022;38(9):373-381
pubmed: 36093265
Nature. 2022 Dec;612(7941):S48-S49
pubmed: 36536213
Risk Manag Healthc Policy. 2021 Mar 12;14:1033-1039
pubmed: 33737844
Health Aff (Millwood). 2016 Feb;35(2):199-207
pubmed: 26858370
Malar J. 2021 Jul 27;20(1):325
pubmed: 34315489
PLoS One. 2022 Jun 3;17(6):e0269273
pubmed: 35657814
Malar J. 2018 May 2;17(1):187
pubmed: 29720172
mBio. 2016 Apr 26;7(2):e00514-16
pubmed: 27118593
Malar J. 2022 Apr 25;21(1):132
pubmed: 35468801
Niger J Med. 2010 Jan-Mar;19(1):8-13
pubmed: 20232750
PLoS One. 2018 Jun 15;13(6):e0199172
pubmed: 29906275
Lancet. 2015 Jul 4;386(9988):31-45
pubmed: 25913272